Damora Therapeutics (DMRA) Interest Expenses (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Interest Expenses came in at $11.4 million in Q1 2026, up 12879.07% YoY from N/an in Q1 2025, and up 228331.6% on a QoQ basis from $5000.0 in Q4 2025.
Damora Therapeutics (DMRA) Interest Expenses (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Interest Expenses data on file, last reported at $11.4 million in Q1 2026.
- Quarterly Interest Expenses rose 12879.07% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (up 12879.07% YoY) and the FY2025 annual result came in at $75.4 million, up 12.2% from the prior year.
- Interest Expenses climbed to $11.4 million in Q1 2026, from $5000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $11.4 million in Q1 2026 to a low of $5000.0 in Q4 2025.
- A 5-year average of $1.0 million and a median of $120000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses tumbled 98.53% — and 2026, when it soared 12879.07%.
- Tracing DMRA's Interest Expenses over 5 years: stood at $155000.0 in 2022, then advanced by 10.32% to $171000.0 in 2023, then slumped by 80.7% to $33000.0 in 2024, then plunged by 84.85% to $5000.0 in 2025, then soared by 228331.6% to $11.4 million in 2026.
- The last three Interest Expenses figures came in at $11.4 million (Q1 2026), $5000.0 (Q4 2025), and $20000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 11.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.07 Mn |
| Jun 30, 2026 | 11.07 Mn |
| Mar 31, 2026 | 11.42 Mn |
| Mar 31, 2026 | 11.42 Mn |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 48,000.00 |
| Jun 30, 2024 | 48,000.00 |
| Mar 31, 2024 | 92,000.00 |
| Mar 31, 2024 | 92,000.00 |